MYLOTARG®

(Gemtuzumab ozogamicin)

Documentation

Patented
Approved 2000
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: ADC ADCC
Target: CD33
Indication Category: Cancer

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA